HALOZYME THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$452M
↑+51.6% +$154Mvs FY2024 (Q4)
Gross Profit
$373M
↑+45.7% +$117Mvs FY2024 (Q4)
Operating Income
$290M
↑+65.4% +$115Mvs FY2024 (Q4)
Net Income
$245M
↑+78.5% +$108Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $452M | $298M |
| COGS | $79M | $42M |
| Gross Profit | $373M | $256M |
| R&D | $0 | $20M |
| SG&A | $77M | $42M |
| D&A | $3M | $3M |
| Other OpEx | $2M | $15M |
| Operating Income | $290M | $176M |
| Interest Exp. | $5M | $5M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $285M | $171M |
| Tax | $41M | $34M |
| Net Income | $245M | $137M |
QuarterCharts · SEC EDGAR data · HALO · Comparing FY2025 (Q4) vs FY2024 (Q4)